US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by LENZ Therapeutics, Inc.

News headline image
LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
News headline image
LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
News headline image
LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
News headline image
LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
News headline image
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
News headline image
LENZ Therapeutics to Participate in Upcoming Investor Conferences
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
News headline image
LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
News headline image
LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
News headline image
LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
News headline image
LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
News headline image
LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
News headline image
LENZ Therapeutics to Present at Upcoming Investor Conferences
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
News headline image
LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
News headline image
LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
News headline image
LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
News headline image
LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
News headline image
LENZ Therapeutics to Present at Upcoming Investor Conferences
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
News headline image
LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
News headline image
LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
News headline image
LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
News headline image
LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
News headline image
LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
News headline image
LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
News headline image
LENZ Therapeutics Announces NMPA Submission of New Drug Application for LNZ100 in China for the Treatment of Presbyopia
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
News headline image
LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
News headline image
LENZ Therapeutics to Present at Upcoming Investor Conferences
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
News headline image
LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
News headline image
LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
News headline image
LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ
News headline image
LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Tickers LENZ